1 published article · Updated continuously
24 trials tracked for Bone loss: 8 in phase 3 or 4 and 1 with published results. The most-cited published study has 11 citations.
Showing the 24 most-cited and recently-updated of 24 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Several pharmacological interventions have demonstrated efficacy in managing bone mineral density (BMD). Romosozumab showed a significant increase in postero-anterior lumbar spine BMD at 12 months compared to the control group 7. Zoledronic acid was associated with significant improvements in lumbar spine BMD over periods ranging from 12 months to 5 years 9, and also demonstrated significant differences in hip and femoral neck bone mass density compared to placebo 13.
Other treatments showed varying results. Teriparatide was evaluated across multiple trials; while it showed no statistically significant difference in total hip, lumbar spine, or femoral neck BMD compared to control 17, it remains a recognized intervention for the condition [6, 15]. Risedronate was associated with a lower incidence of vertebral fractures compared to the control group 4. Denosumab showed a statistically significant increase in postero-anterior lumbar spine bone mineral density at 12 months 8.
AI synthesis of 8 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
